S. Theoleyre, Y. Wittrant, S. K. Tat, Y. Fortun, F. Redini et al., The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine & Growth Factor Reviews, vol.15, issue.6, pp.457-475, 2004.
DOI : 10.1016/j.cytogfr.2004.06.004

T. L. Burgess, Y. Qian, S. Kaufman, B. D. Ring, G. Van et al., The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts, The Journal of Cell Biology, vol.108, issue.3, pp.527-538, 1999.
DOI : 10.1016/0006-291X(89)91143-1

H. Hsu, D. L. Lacey, C. R. Dunstan, I. Solovyev, A. Colombero et al., Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, Proceedings of the National Academy of Sciences, vol.96, issue.7, pp.3540-3545, 1999.
DOI : 10.1073/pnas.96.7.3540
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC22329

E. Tsuda, M. Goto, S. Mochizuki, K. Yano, F. Kobayashi et al., Isolation of a Novel Cytokine from Human Fibroblasts That Specifically Inhibits Osteoclastogenesis, Biochemical and Biophysical Research Communications, vol.234, issue.1, pp.137-142, 1997.
DOI : 10.1006/bbrc.1997.6603

W. S. Simonet, D. L. Lacey, C. R. Dunstan, M. Kelley, M. S. Chang et al., Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density, Cell, vol.89, issue.2, pp.309-319, 1997.
DOI : 10.1016/S0092-8674(00)80209-3

J. G. Emery, P. Mcdonnell, M. B. Burke, K. C. Deen, S. Lyn et al., Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL, Journal of Biological Chemistry, vol.273, issue.23, pp.14363-14367, 1998.
DOI : 10.1074/jbc.273.23.14363

S. R. Wiley, K. Schooley, P. J. Smolak, W. S. Din, C. P. Huang et al., Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity, vol.3, issue.6, pp.673-682, 1995.
DOI : 10.1016/1074-7613(95)90057-8

P. H. Bolton-maggs and K. J. Pasi, Haemophilias A and B, The Lancet, vol.361, issue.9371, pp.1801-1809, 2003.
DOI : 10.1016/S0140-6736(03)13405-8

J. E. Sadler, New Concepts in Von Willebrand Disease, Annual Review of Medicine, vol.56, issue.1, pp.173-191, 2005.
DOI : 10.1146/annurev.med.56.082103.104713

L. J. Suva, E. Hartman, J. D. Dilley, S. Russell, N. S. Akel et al., Platelet Dysfunction and a High Bone Mass Phenotype in a Murine Model of Platelet-Type von Willebrand Disease, The American Journal of Pathology, vol.172, issue.2, pp.430-439, 2008.
DOI : 10.2353/ajpath.2008.070417

C. S. Kovacs, Hemophilia, low bone mass, and osteopenia/osteoporosis, Transfusion and Apheresis Science, vol.38, issue.1, pp.33-40, 2008.
DOI : 10.1016/j.transci.2007.12.003

T. A. Wallny, D. T. Scholz, J. Oldenburg, C. Nicolay, S. Ezziddin et al., Osteoporosis in haemophilia ? an underestimated comorbidity?, Haemophilia, vol.292, issue.1, pp.79-84, 2007.
DOI : 10.1053/jinf.2002.1109

J. J. Dumas, R. Kumar, T. Mcdonagh, F. Sullivan, M. L. Stahl et al., Crystal Structure of the Wild-type von Willebrand Factor A1-Glycoprotein Ib?? Complex Reveals Conformation Differences with a Complex Bearing von Willebrand Disease Mutations, Journal of Biological Chemistry, vol.279, issue.22, pp.23327-23334, 2004.
DOI : 10.1074/jbc.M401659200

T. Adachi, T. Matsushita, Z. Dong, A. Katsumi, T. Nakayama et al., Identification of amino acid residues essential for heparin binding by the A1 domain of human von Willebrand factor, Biochemical and Biophysical Research Communications, vol.339, issue.4, pp.1178-1183, 2006.
DOI : 10.1016/j.bbrc.2005.11.126

N. Maita, K. Nishio, E. Nishimoto, T. Matsui, Y. Shikamoto et al., Crystal Structure of von Willebrand Factor A1 Domain Complexed with Snake Venom, Bitiscetin: INSIGHT INTO GLYCOPROTEIN Ib?? BINDING MECHANISM INDUCED BY SNAKE VENOM PROTEINS, Journal of Biological Chemistry, vol.278, issue.39, pp.37777-37781, 2003.
DOI : 10.1074/jbc.M305566200

K. Fukuda, T. A. Doggett, L. A. Bankston, M. A. Cruz, T. G. Diacovo et al., Structural Basis of von Willebrand Factor Activation by the Snake Toxin Botrocetin, Structure, vol.10, issue.7, pp.943-950, 2002.
DOI : 10.1016/S0969-2126(02)00787-6

A. C. Zannettino, C. A. Holding, P. Diamond, G. J. Atkins, P. Kostakis et al., Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor, Journal of Cellular Physiology, vol.156, issue.2, pp.714-723, 2005.
DOI : 10.1002/jcp.20354

S. Shahbazi, P. J. Lenting, C. Fribourg, V. Terraube, C. V. Denis et al., Characterization of the interaction between von Willebrand factor and osteoprotegerin, Journal of Thrombosis and Haemostasis, vol.98, issue.9, pp.1956-1962, 2007.
DOI : 10.1111/j.1538-7836.2007.02681.x

L. Duplomb, M. Baud-'huin, C. Charrier, M. Berreur, V. Trichet et al., Phosphorylation of Signal Transducer and Activator of Transcription 3, Endocrinology, vol.149, issue.7, pp.3688-3697, 2008.
DOI : 10.1210/en.2007-1719
URL : https://hal.archives-ouvertes.fr/inserm-00667501

S. F. Altschul, W. Gish, W. Miller, E. W. Myers, and D. J. Lipman, Basic local alignment search tool, Journal of Molecular Biology, vol.215, issue.3, pp.403-410, 1990.
DOI : 10.1016/S0022-2836(05)80360-2

M. A. Larkin, G. Blackshields, N. P. Brown, R. Chenna, P. A. Mcgettigan et al., Clustal W and Clustal X version 2.0, Bioinformatics, vol.23, issue.21, pp.2947-2948, 2007.
DOI : 10.1093/bioinformatics/btm404
URL : https://hal.archives-ouvertes.fr/hal-00206210

M. Clamp, J. Cuff, S. M. Searle, and G. J. Barton, The Jalview Java alignment editor, Bioinformatics, vol.20, issue.3, pp.426-427, 2004.
DOI : 10.1093/bioinformatics/btg430

A. Sali and T. L. Blundell, Comparative Protein Modelling by Satisfaction of Spatial Restraints, Journal of Molecular Biology, vol.234, issue.3, pp.779-815, 1993.
DOI : 10.1006/jmbi.1993.1626

S. Ito, K. Wakabayashi, O. Ubukata, S. Hayashi, F. Okada et al., Crystal Structure of the Extracellular Domain of Mouse RANK Ligand at 2.2-A Resolution, Journal of Biological Chemistry, vol.277, issue.8, pp.6631-6636, 2002.
DOI : 10.1074/jbc.M106525200

W. Humphrey, A. Dalke, and K. Schulten, VMD: Visual molecular dynamics, Journal of Molecular Graphics, vol.14, issue.1, pp.33-38, 1996.
DOI : 10.1016/0263-7855(96)00018-5

X. Cheng, M. Kinosaki, M. Takami, Y. Choi, H. Zhang et al., Disabling of Receptor Activator of Nuclear Factor-??B (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo, Journal of Biological Chemistry, vol.279, issue.9, pp.8269-8277, 2004.
DOI : 10.1074/jbc.M309690200

D. Palma, A. F. Cotler, and J. M. , Hemophilic Arthropathy, Archives of Surgery, vol.72, issue.2, pp.247-250, 1956.
DOI : 10.1001/archsurg.1956.01270200063011

L. A. Valentino, N. Hakobyan, N. Rodriguez, and W. K. Hoots, Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage, Haemophilia, vol.43, issue.1, pp.10-13, 2007.
DOI : 10.1111/j.1365-2516.2005.01080.x

F. P. Lafeber, P. Miossec, and L. A. Valentino, Physiopathology of haemophilic arthropathy, Haemophilia, vol.13, issue.3, pp.3-9, 2008.
DOI : 10.1002/art.21211

A. E. Kearns, S. Khosla, and P. J. Kostenuik, Receptor Activator of Nuclear Factor ??B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease, Endocrine Reviews, vol.29, issue.2, pp.155-192, 2008.
DOI : 10.1210/er.2007-0014

B. Bolon, G. Campagnuolo, and U. Feige, Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis, Cellular and Molecular Life Sciences (CMLS), vol.59, issue.9, pp.1569-1576, 2002.
DOI : 10.1007/s00018-002-8530-7

N. Bucay, I. Sarosi, C. R. Dunstan, S. Morony, J. Tarpley et al., osteoprotegerin-deficient mice develop early onset osteoporosis and arterial??calcification, Genes & Development, vol.12, issue.9, pp.1260-1268, 1998.
DOI : 10.1101/gad.12.9.1260
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC316769

F. Bilora, E. Zanon, F. Petrobelli, M. Cavraro, P. Prandoni et al., Does Hemophilia Protect Against Atherosclerosis? A Case-Control Study, Clinical and Applied Thrombosis/Hemostasis, vol.37, issue.3, pp.193-198, 2006.
DOI : 10.1177/107602960601200207

J. Astermark, P. Petrini, L. Tengborn, S. Schulman, R. Ljung et al., Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized, British Journal of Haematology, vol.31, issue.2, pp.1109-1113, 1999.
DOI : 10.1046/j.1365-2796.1997.130135000.x

M. J. Manco-johnson, T. C. Abshire, A. D. Shapiro, B. Riske, M. R. Hacker et al., Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia, New England Journal of Medicine, vol.357, issue.6, pp.535-544, 2007.
DOI : 10.1056/NEJMoa067659

R. W. Johnstone, A. J. Frew, and M. J. Smyth, The TRAIL apoptotic pathway in cancer onset, progression and therapy, Nature Reviews Cancer, vol.3, issue.10, pp.782-798, 2008.
DOI : 10.1038/sj.leu.2403491

G. Pan, J. Ni, Y. F. Wei, G. Yu, R. Gentz et al., An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL, Science, vol.277, issue.5327, pp.815-818, 1997.
DOI : 10.1126/science.277.5327.815

R. Pawlinski and N. Mackman, Use of Mouse Models to Study the Role of Tissue Factor in Tumor Biology, Seminars in Thrombosis and Hemostasis, vol.34, issue.02, pp.182-186, 2008.
DOI : 10.1055/s-2008-1079258

B. Ho-tin-noe, T. Goerge, S. M. Cifuni, D. Duerschmied, D. D. Wagner et al., Platelet Granule Secretion Continuously Prevents Intratumor Hemorrhage, Cancer Research, vol.68, issue.16, pp.6851-6858, 2008.
DOI : 10.1158/0008-5472.CAN-08-0718
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2547489

M. Franchini, G. Targher, F. Manzato, and G. Lippi, Acquired factor VIII inhibitors in oncohematology: A systematic review, Critical Reviews in Oncology/Hematology, vol.66, issue.3, pp.194-199, 2008.
DOI : 10.1016/j.critrevonc.2007.12.004

S. L. Meeks, J. F. Healey, E. T. Parker, R. T. Barrow, and P. Lollar, Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors, Blood, vol.112, issue.4, pp.1151-1153, 2008.
DOI : 10.1182/blood-2008-01-132639